Experiencia de 22 años de trasplante autólogo de células hematopoyéticas en pacientes con mieloma múltiple o amiloidosis sistémica. 1992-2014

Sarmiento, Mauricio; Lira, P; Ocqueteau, Mauricio; Rodríguez, María Alejandra; García, Maria José; Jara, Verónica; Bertín, Pablo; Ramírez, Pablo

doi:10.4067/s0034-98872014001200001

Cited by 5 publications

(5 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…La edad promedio fue de 64,5 años, similar a lo descrito internacionalmente de, aproximadamente, 65 años. La edad media observada en la cohorte latinoamericana fue de 60 años 9 , lo que podría mostrar una diferencia con los estudios europeos o norteamericanos, en que el MM se presenta en pacientes mayores.…”

Section: Discussionunclassified

“…En cuanto al tipo de MM, encontramos un bajo número de MM de CL (solo 9%), similar resultado a la anterior cohorte chilena 4 . Esto no se reprodujo en el estudio latinoamericano 9 , que reportó 16%. No tenemos clara la causa de este subdiagnóstico en nuestro país, pero es posible que se trate de la interpretación errónea de la electroforesis de proteínas por parte de la comunidad médica, en el sentido de que este tipo de MM se presenta generalmente con hipogammaglobulinemia sin un componente monoclonal.…”

Section: Discussionunclassified

“…En un comienzo, el régimen elegido fue taldex, basado en los buenos resultados obtenidos en ese entonces para candidatos a TAPH [27][28][29] . De hecho, en los servicios públicos de Latinoamérica, el taldex es uno de los regímenes más usados 9 .…”

Section: Discussionunclassified

“…Existe además otro reporte de 50 pacientes del Hospital Naval de Valparaíso 6 . También es posible encontrar mayor información sobre tratamiento y sobrevida en MM, especialmente de parte de los grupos que realizan trasplante en nuestro país [7][8][9] .…”

unclassified

See 3 more Smart Citations

Mieloma múltiple en Chile: pasado, presente y futuro del programa nacional de drogas antineoplásicas (PANDA). Revisión de 1.103 pacientes

Peña

Rojas

Rojas³

et al. 2018

Rev. méd. Chile

View full text Add to dashboard Cite

Survival of 1,103 Chilean patients with multiple myeloma receiving different therapeutic protocols from 2000 to 2016 Background: Multiple myeloma (MM) is one of the most common malignancies found in hematology. Aim: To describe the features of patients with MM and perform a survival analysis according to the different treatment protocols used between 2000 and 2016. Material and Methods: Analysis of the database of the Chilean national anti-neoplastic drug program. Information was obtained from 1,103 patients, with a median age of 64.5 years (range 27-95) and a male to female ratio of 1:1.2. Results: The mean overall survival (OS) of patients receiving or not receiving Thalidomide was 46 and 30 months, respectively (p < 0.01). The mean OS of patients treated before 2007 (treated with melphalan and prednisone) and between 2007 and 2012 (treated with thalidomide and dexamethasone) was 36 and 48 months respectively. In the group starting in 2013 (treated with cyclophosphamide, thalidomide and dexamethasone) the median survival had not been reached at 20 months of follow up (p = 0.01 for all comparisons). Autologous transplantation (AT) was carried out in only 18% of the eligible patients. The median OS of the patients who receive an AT had not been reached at 48 month compared with 36 month among those who did not received the procedure (p < 0.01). Conclusions: Even though overall survival has improved with time, new drugs must be introduced in our protocols to obtain similar results to those obtained worldwide.

show abstract

Section: Discussionunclassified

unclassified

See 2 more Smart Citations

Mieloma múltiple en Chile: pasado, presente y futuro del programa nacional de drogas antineoplásicas (PANDA). Revisión de 1.103 pacientes

Peña

Rojas

Rojas³

et al. 2018

Rev. méd. Chile

View full text Add to dashboard Cite

show abstract

“…Unfortunately, the bone marrow transplant program in the Chilean public health system is restricted, and amyloidosis is not currently an indication of it, which explains why no patient had bone marrow transplant in our registry. Furthermore, there is just one report in Chile of 6 AL amyloidosis patients with bone marrow transplant 40 .…”

Section: Autologous Stem Cell Transplantationmentioning

confidence: 99%

AL amyloidosis in the Chilean public health system: a pending debt. Multicenter study of the Chilean Monoclonal Gammopathies Cooperative Group

et al. 2019

View full text Add to dashboard Cite

Background: Immunoglobulin light chain (AL) amyloidosis is a rare and underdiagnosed entity. Aim: To characterize patients with AL amyloidosis in Chilean public health centers. Material and Methods: We conducted a retrospective, multicenter study. Public centers of the Chilean Monoclonal Gammopathies Cooperative Group were asked to search for patients with AL amyloidosis in their databases. Epidemiological, clinical and laboratory characteristics were evaluated. Results: Forty-two patients aged 22 to 84 years were found. Twenty four percent had localized AL amyloidosis; 64% had a lambda light chain clone; 47% were associated with multiple myeloma and 9% with non-Hodgkin lymphoma. The most commonly involved organ was the kidney (76%). Serum free light chains were measured in 31% and an echocardiogram was performed in 74% of patients. Seventeen percent of patients received only palliative care, 17% were treated with bortezomib, 21% with thalidomide, and 40% with melphalan. No patient was transplanted. The mean overall survival (OS) of the group was 19 months. The 5-year OS was 28%. Conclusions: It is important to obtain these realistic, national data to initiate strategies to improve early diagnosis and proper management of this disease.

show abstract

Trasplante autólogo de células madre hematopoyéticas en pacientes con diagnóstico de mieloma múltiple, experiencia en 9 años

Jaramillo

Useche

García

et al. 2018

Revista Colombiana de Cancerología

View full text Add to dashboard Cite

Experiencia de 22 años de trasplante autólogo de células hematopoyéticas en pacientes con mieloma múltiple o amiloidosis sistémica. 1992-2014

Cited by 5 publications

References 12 publications

Mieloma múltiple en Chile: pasado, presente y futuro del programa nacional de drogas antineoplásicas (PANDA). Revisión de 1.103 pacientes

Mieloma múltiple en Chile: pasado, presente y futuro del programa nacional de drogas antineoplásicas (PANDA). Revisión de 1.103 pacientes

AL amyloidosis in the Chilean public health system: a pending debt. Multicenter study of the Chilean Monoclonal Gammopathies Cooperative Group

Trasplante autólogo de células madre hematopoyéticas en pacientes con diagnóstico de mieloma múltiple, experiencia en 9 años

Contact Info

Product

Resources

About